Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim versus rhG-CSF for prevention of chemotherapy-related neutropenia in non-small cell lung cancer
ChiCTR1800020351Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Incidence of grade III/IV absolute neutrophil count reduction. Started Dec 2018; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800020351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020351.